openPR Logo
Press release

Co-Chairs Centrexion Therapeutics & Metys Pharmaceuticals invite to SMi’s 19th Annual Pain Therapeutics

02-26-2019 05:31 PM CET | Health & Medicine

Press release from: SMi Group

pain, pain therapeutics, migraine, headache therapy, analgesic, peripheral neuropathy

pain, pain therapeutics, migraine, headache therapy, analgesic, peripheral neuropathy

SMi reports: Invitations from the conference co-chairs has been released for the upcoming Pain Therapeutics conference in May this year.

On the 13th and 14th May 2019 in London, SMi will host the 19th Annual Pain Therapeutics Conference, which will explore the cutting-edge research of novel therapeutic targets in the pipeline of leading pharmaceutical companies and discuss solutions for the challenges of clinical trial design and conduct.

SMi are delighted to have Kerrie Brady, Chief Business Officer, Centrexion Therapeutics and Michael Scherz, Founder & CEO, Metys Pharmaceuticals co-chairing the two-day conference.

The co-chairs invite letter states:

“It has been a memorable year for the global pain drug development community.

The first regulatory approvals for CGRP migraine drugs in the US and Europe have ushered in a novel pharmacological strategy for treating and preventing migraine. On the other hand, Nav1.7 inhibitors had significant challenges in their clinical development, as clinical trial results have been less than encouraging.

The FDA have awarded, for the first time ever, the Breakthrough designation to promising new pain drugs; and the Agency has promised new guidelines that govern the development of novel therapeutics options for the treatment of pain. The US National Institutes of Health have received $500M in additional funding to facilitate the development of new approaches to pain drug development.

Pain management is a global concern: the European Horizon 2020 “Towards Transatlantic Co-operation in Pain Research” meeting between leading researchers, clinicians, patient groups and government agencies has recommended collaboration priorities for the EU and North America in research on pain and to accelerate access to better and safer pain treatments.

Clearly, major changes and challenges are afoot in the novel pain therapeutics ecosystem. Will they make a difference in how we develop new analgesic therapies? Will they lead to new treatments for patients?

As the co-chairs for the 19th SMi Conference on Pain Therapeutics Conference promises a timely review of new therapies and a survey of the breakthroughs and breakdowns of the past year. New clinical trial methodologies will be discussed. Progress from ongoing development efforts will be reported. Interactive round table discussions will allow us all to participate and learn from each other. We'll refresh our collegial connections and friendships.

Join us for a stimulating series of presentations by leaders in our growing field of novel pain therapeutics.

We look forward to welcoming you in London in May 2019.”

For further information on the full two-day agenda and speaker line up, visit

For those who are interested in attending the conference, there is a £300 Early Bird discount on bookings expiring at midnight on Thursday 28th February 2019. Places can be reserved at

Pain Therapeutics 2019 is proudly sponsored by CHDR, Lotus Clinical Research, MD Biosciences.

We have tailored sponsorship packages available, if you are interested contact Alia Malick, Director, on +44 (0) 20 827 6168 or email

For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6000 or

Pain Therapeutics 2019
13 – 14 May 2019
Copthorne Tara Hotel, London, UK

Follow us @SMiPharm

About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at

Marketing Dept, Ground Floor
45 Curlew Street, London

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Co-Chairs Centrexion Therapeutics & Metys Pharmaceuticals invite to SMi’s 19th Annual Pain Therapeutics here

News-ID: 1618597 • Views: 581

More Releases from SMi Group

Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Con …
SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation. Industry leaders will uncover the
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK. With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022. With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week. With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman. The

All 5 Releases

More Releases for Pain

Cold Pain Therapy Market
Allied Market Research (USA, Oregon, Portland) Published Latest Report titled, ‘Cold Pain Therapy Market: Global Opportunity Analysis and Industry Forecast 2020-2027’. The Cold Pain Therapy Market is expected to witness growth in upcoming years due to factors such as increase in target patient population, which mostly includes patients suffering from cancer, tuberculosis and cardiovascular diseases. This market research study determines the increase in changes and the aspects which are likely to have
Global Pain Management Drugs & Devices Market By Application - Burn Pain, Cancer …
Researchmoz added Most up-to-date research on "Global Pain Management Drugs & Devices Market By Application - Burn Pain, Cancer Pain, Dental/Facial Pain, Migraine Headache Pain & Musculoskeletal Pain" to its huge collection of research reports. This report studies Pain Management Drugs & Devices in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016,
Pain Management Devices Market
ReportsWorldwide has announced the addition of a new report title Pain Management Devices Market to its growing collection of premium market research reports. For a Detailed description and table of contents of this report please click here: More than 100 million people in the US experience chronic pain. In Europe, the prevalence of chronic pain is between 25% and 35%. Pain-related disability represents a significant and costly liability to patients
Boot chronic pain
For immediate release Due to our rushed lives and stressful environment, many people are suffering from chronic pain and fatigue. We feel permanently tired and are barely able to get through our normal day. One is able to change this status when following the guidelines the book "Tired of being Tired to the point of being Gatvol (Fed Up). Some people will need a team of medical practitioners to help them
Targeting chronic pain
With the support of the Austrian Science Fund FWF, the neurophysiologist Ruth Drdla-Schutting is investigating the role astrocytes play in the genesis of chronic pain. With the help of innovative gene technology (DREADDs), scientists are tailoring treatment specifically to these cells that are the most numerous found in the central nervous system. Pain is an important protection system of the human body. But when it becomes chronic, as it frequently
Complex Regional Pain Syndrome
“Complex Regional Pain Syndrome Global 2016 Clinical Trials Review, H2" provides an detailed overview of Complex Regional Pain Syndrome scenario. Report includes top line data relating on Complex Regional Pain Syndrome Global clinical trials scenario. This report on Complex Regional Pain Syndrome also includes an review of trial numbers as well as their ( Complex Regional Pain Syndrome ) average enrollment in uppermost/top countries which are conducted worldwide. Complex Regional